Podocyturia: why it may have added value in rare diseases

Abstract

Fabry disease is an inherited lysosomal disease in which defects in the GLA gene lead to α-galactosidase-A deficiency, and accumulation of glycosphingolipids, including lyso-Gb3, a podocyte stressor. Therapy is available as enzyme replacement therapy and, for some patients, the chaperone migalastat. A key decision is when to start therapy, given its costs and potential impact on some aspects of quality of life. The decision is especially difficult in otherwise asymptomatic patients. A delayed start of therapy may allow kidney injury to progress subclinically up to the development of irreversible lesions. Non-invasive tools to monitor subclinical kidney injury are needed. One such tool may be assessment of podocyturia. In this issue of CKJ, [Trimarchi H, Canzonieri R, Costales-Collaguazo C et al. Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes. Clin Kidney J 2019; doi.org/10.1093/ckj/sfy053] report on podocyturia assessment in Fabry nephropathy. Specifically, they report that podocalyxin may be lost from detached urinary podocytes.

Fabry disease is a hereditary metabolic disorder characterized by accumulation of glycosphingolipids that leads to chronic kidney disease (CKD), heart disease and stroke, among others [1]. Fabry nephropathy is one of the few nephropathies that has a specific therapy. Currently, both a chaperone, migalastat, and a recombinant enzyme, agalsidase, are approved for the treatment of Fabry disease, in which mutations in the GLA gene lead to absent or inactive lysosomal α-galactosidase-A.

Podocyturia is the urinary loss of podocytes. Since podocytes are terminally differentiated cells that do not divide and have limited replacement potential in adults, loss of podocytes in urine is thought to contribute to progressive podocyte depletion and CKD progression. More than a decade ago, the potential of podocyturia to detect early kidney injury, preceding pathological albuminuria, or to identify active disease versus scar-related proteinuria, was already acknowledged [2]. However, the diverse techniques used to assess podocyturia (microscopy of stained cells, proteomics-based assays or mRNA quantification) have not yet been standardized to the point that they may enter/be used in clinical practice [3–8]. Antibodies against several podocyte proteins have been used to stain for them in urine and different authors have reported increased podocyturia in Fabry disease when assessed by podocalyxin staining [5–8]. Both podocalyxin and synaptopodin are used to identify podocytes in urine. However, few authors have stained for both proteins, and when they have, they did not report whether results differed depending on the marker used [9]. In this issue of CKJ, Trimarchi et al. report that in Fabry nephropathy, podocalyxin may be lost from detached urinary podocytes before synaptopodin expression is lost [10]: all control urinary podocytes colocalized synaptopodin and podocalyxin, whereas in Fabry patients, most podocytes only stained for synaptopodin and no podocalyxin-positive/synaptopodin-negative cells were observed. One practical consequence would be that podocalyxin staining may underestimate podocyturia. In this regard, Trimarchi et al. hypothesize that a decrease in podocalyxin may be associated with less adhesiveness of cells to the extracellular matrix, favouring detachment and urinary excretion.

In Fabry disease, observations regarding the relationship of podocyturia with albuminuria or glomerular filtration rate (GFR) were not concordant [5–8]. Given the low number and heterogeneity of studied patients, this is not surprising. In this regard, several dynamic processes may influence the association of podocyturia with analytical evidence of kidney injury or progression. Thus, an increase in podocyturia appears to precede the increase in albuminuria, but progressive loss of podocytes and glomeruli reflected in decreasing GFR may, in turn, decrease podocyturia [11]. Alternatively, as suggested by Trimarchi et al., phenotypic changes may influence urinary podocyte quantification results when antibodies with different specificities are used [10]. Although it was a cross-sectional study, patients in whom urinary podocytes co-localized both proteins had higher podocyturia and lower proteinuria. One potential interpretation is that this represents an earlier stage of the disease, in which the podocyte phenotype has not yet been compromised, which is followed, when disease progresses, by selective podocalyxin depletion [10]. However, alternative explanations are possible. Podocalyxin-negative, synaptopodin-positive cells may represent cells other than podocytes. In this regard, according to the Protein Atlas, some anti-synaptopodin antibodies may faintly stain tubular cells (https://www.proteinatlas.org/ENSG00000171992-SYNPO/tissue/kidney#img; accessed 17 July 2018), or the test for synaptopodin staining may be more sensitive than the test for podocalyxin staining. However, preservation over time of staining in stored urine should not be an issue, since all samples were collected on site.

What needs to be done now? The hypothesis that podocalyxin may be lost earlier than synaptopodin in injured Fabry podocytes should be tested in renal biopsies from Fabry patients.

What might be the mechanisms underlying the early podocalyxin loss? Injured podocytes may lose or decrease the expression of podocyte-specific proteins. Podocalyxin is the major sialoprotein of the glycocalyx of podocyte bodies and foot processes and locates mainly to urinary surfaces, above the level of slit diaphragms [12]. Synaptopodin is a cytoskeletal protein present in the foot processes of podocytes, and its expression is also markedly diminished in the kidneys under proteinuric conditions [13]. Podocalyxin expression commences at the early S-shaped body stage, and is required for the formation and maintenance of podocyte foot processes [14], whereas synaptopodin appears later, coinciding with the formation of foot processes and is restricted to the basal portion of the podocytes, where foot processes form [15] (Figure 1A). Decreased glomerular podocalyxin immunostaining has been reported in primary glomerulonephritides associated with nephrotic syndrome and in diabetic nephropathy, although synaptopodin was not explored [16, 17]. In more detailed studies, podocalyxin and synaptopodin expression was preserved in non-sclerotic glomeruli form minimal change disease and membranous nephropathy. By contrast, in idiopathic or HIV-associated collapsing focal segmental glomerulosclerosis, 16% of the histologically unaffected glomeruli showed marked reduction of synaptopodin expression but not of podocalyxin (Figure 1B) [15]. This is in contrast to the urinary findings of Trimarchi et al. in Fabry disease (Figure 1C). As an extracellular protein, podocalyxin may be targeted by extracellular enzymes. This may change the antigenicity or disrupt the protein and/or function. Indeed, podocyte injury may result in desialylation of podocalyxin [18]. Different antibodies may recognize different podocalyxin forms [19].

FIGURE 1.

Graphic representation of podocalyxin and synaptopodin. (A) Normal healthy podocytes. Note foot processes and podocalyxin presence in the urinary surface, above the slit diaphragm that connects two adjacent foot processes. (B) Artistic rendition of the loss of synaptopodin with preservation of podocalyxin as described for collapsing focal segmental glomerulosclerosis [15]. (C) Potential appearance of a Fabry podocyte pre-detachment. Artistic rendition based on Trimarchi et al. findings in the urine of Fabry patients [10]. Note foot process effacement and loss of podocalyxin-containing glycocalyx.

What might be the drivers of podocalyxin loss? The urine podocalyxin/synaptopodin ratio was decreased in diabetic nephropathy as compared with other glomerulonephritides [20]. This may mimic the urinary findings of Trimarchi et al. in Fabry disease. Indeed, both nephropathies may be considered metabolic proteinuric forms of progressive CKD. A high glucose concentration suppressed podocalyxin expression in cultured podocytes, but synaptopodin was not studied [21]. Lyso-Gb3 is a metabolite accumulated in Fabry disease that induces a podocyte stress response similar to that induced by high glucose concentrations [22, 23]. In addition, lyso-Gb3 increases CD80 expression in podocytes, a marker found both in Fabry kidney biopsies and in the urine of Fabry patients [8]. This supports studying the impact of lyso-Gb3 on podocalyxin expression.

Two characteristics of Fabry disease emphasize the potential importance of podocyturia assessment. First, the natural history is several decades long and the first clinical evidence of kidney injury, which is usually microalbuminuria, may take decades to develop. Secondly, by the time kidney injury becomes clinically evident, irreversible lesions may have developed. In this regard, the timing of therapy initiation is an important consideration, given the high cost of therapy and the burden of intravenous administration in the case of the agalsidase.

Reports that increased podocyturia may precede pathological albuminuria in Fabry disease open the door to a non-invasive assessment of early kidney injury that may eventually be used to initiate therapy when there is no other indication. Only further research will guide the choice of the podocyturia assay that may eventually make it into clinical practice. Although normalization of podocyturia by urinary creatinine is the current standard, and may be useful to compare the same patient over time, urinary creatinine depends mainly on muscle mass and may vary up to 4-fold between individuals, potentially resulting in similar (up to 4-fold) interindividual variations in creatinuria-normalized podocyturia in different patients with similar rates of podocyte loss. The lower muscle mass (and urinary creatinine) in females may lead to higher urinary podocyte:creatinine ratios. Reproducible methods for widespread implementation for podocyturia detection are still lacking, but if podocyturia ever reaches the clinical routine, different threshold levels should be defined for males and females.

FUNDING

The work was supported by ISCIII and FEDER funds PI16/02057, PI18/01366, Sociedad Española de Nefrologia, ISCIII-RETIC REDinREN RD016/009, Miguel Servet to M.D.S.-N., Comunidad de Madrid CIFRA2 B2017/BMD-3686.

CONFLICT OF INTEREST STATEMENT

A.O. is a consultant for and has received research support by Genzyme a Sanofi company and has received speaker fees from Shire and Amicus. M.D.S.-N. has received speaker fees from Genzyme a Sanofi company. R.T. is a consultant for and has received speaker fees from Shire, Amicus and Genzyme a Sanofi company.